NASDAQ : CPRX
Catalyst Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 31.49 USD (Jul 15, 2026, 4:00 PM EDT) · Market cap 3.85B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.85B |
| Enterprise Value | 3.10B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 122.42M |
| Shares Outstanding | 122.42M |
| Shares Change (YoY) | +1.12% |
| Shares Change (QoQ) | -0.41% |
| Owned by Insiders (%) | 5.52% |
| Owned by Institutions (%) | 87.59% |
| Float | 115.62M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 18.20 |
| Forward PE | 15.69 |
| PS Ratio | 6.46 |
| Forward PS | 5.88 |
| PB Ratio | 3.80 |
| P/TBV Ratio | 4.33 |
| P/FCF Ratio | 18.52 |
| P/OCF Ratio | 18.51 |
| PEG Ratio | 1.26 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 14.01 |
| EV / Sales | 5.20 |
| EV / EBITDA | 10.14 |
| EV / EBIT | 11.59 |
| EV / FCF | 14.90 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.10 |
| Quick Ratio | 6.70 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 24.50% |
| Return on Assets (ROA) | 16.27% |
| Return on Invested Capital (ROIC) | 78.76% |
| Return on Capital Employed (ROCE) | 26.36% |
| Weighted Average Cost of Capital (WACC) | 8.33% |
| Revenue Per Employee | $3.28M |
| Profits Per Employee | $1.22M |
| Employee Count | 182 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 3.48 |
Taxes
| Measure | Value |
|---|
| Income Tax | 75.14M |
| Effective Tax Rate | 25.34% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +44.38% |
| 50-Day Moving Average | 31.21 |
| 200-Day Moving Average | 25.35 |
| Relative Strength Index (RSI) | 70.17 |
| Average Volume (20 Days) | 2,718,042 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.85M |
| Short Previous Month | 7.95M |
| Short % of Shares Out | 6.41% |
| Short % of Float | 6.79% |
| Short Ratio (days to cover) | 4.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 596.96M |
| Gross Profit | 501.66M |
| Operating Income | 267.64M |
| Pretax Income | 296.46M |
| Net Income | 221.32M |
| EBITDA | 305.83M |
| EBIT | 267.64M |
| Earnings Per Share (EPS) | $1.73 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 755.86M |
| Total Debt | 2.68M |
| Net Cash | 753.18M |
| Net Cash Per Share | $6.15 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 8.29 |
| Working Capital | 807.99M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 208.21M |
| Capital Expenditures | -85,000 |
| Depreciation & Amortization | 38.19M |
| Net Borrowing | n/a |
| Free Cash Flow | 208.13M |
| FCF Per Share | $1.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | 84.04% |
| Operating Margin | 44.83% |
| Pretax Margin | 49.66% |
| Profit Margin | 37.08% |
| EBITDA Margin | 51.23% |
| EBIT Margin | 44.83% |
| FCF Margin | 34.86% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.12% |
| Shareholder Yield | -1.12% |
| Earnings Yield | 5.74% |
| FCF Yield | 5.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $31.67 |
| Price Target Difference | 0.57% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 10.38% |
| EPS Growth Forecast (3Y) | 8.09% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 15.04 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |